“We're looking at opportunities almost on a weekly basis,” Bayer’s pharma chief Stefan Oelrich told Scrip as the German major posted a solid set of financials for the fourth quarter.
Bayer AG's business development activities have been well above most of its industry peers for the past few years and pharma chief Stefan Oelrich has told Scrip that the German group's hunger for more deals is not sated.
Last year, the firm's Leaps by Bayer investment arm added seven groups to its portfolio and participated in a further 15 rounds of financing for already-established portfolio companies. Since 2015,...
Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list
Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.
The Trump administration released more details on “most favored nation” price targets drug companies are expected to apply to US drug prices.
Investors welcomed Bavarian Nordic’s and Bayer’s earnings announcements. However, both stock prices declined over the day of their reports as the impact of recent pressures weighed.
